Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,050 | 1 | 90.6% |
| Food and Beverage | $108.53 | 3 | 9.4% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $1,050 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $108.53 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $1,050 | 1 | Biogen, Inc. ($1,050) |
| 2018 | $39.52 | 1 | Novartis Pharmaceuticals Corporation ($39.52) |
| 2017 | $69.01 | 2 | Novartis Pharmaceuticals Corporation ($69.01) |
All Payment Transactions
4 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/27/2021 | Biogen, Inc. | — | — | Cash or cash equivalent | $1,050.00 | Research |
| Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab Pegol (BIIB133) in Relapsing Multiple Sclerosis. | ||||||
| 04/25/2018 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $39.52 | General |
| Category: NEUROSCIENCE | ||||||
| 04/25/2017 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $42.16 | General |
| Category: NEUROSCIENCE | ||||||
| 01/13/2017 | Novartis Pharmaceuticals Corporation | GILENYA (Drug) | Food and Beverage | In-kind items and services | $26.85 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active-Reference (Ocrelizumab), Parallel-Group, Dose-Ranging Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous Dapirolizumab Pegol (BIIB133) in Relapsing Multiple Sclerosis. | Biogen, Inc. | $1,050 | 1 |
About Dr. Samia Khoury, MD
Dr. Samia Khoury, MD is a Neurology healthcare provider based in Brookline, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1487635322.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Samia Khoury, MD has received a total of $1,159 in payments from pharmaceutical and medical device companies, with $1,050 received in 2021. These payments were reported across 4 transactions from 2 companies. The most common payment nature is "" ($1,050).
Practice Information
- Specialty Neurology
- Location Brookline, MA
- Active Since 11/08/2005
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1487635322
Products in Payments
- GILENYA (Drug) $108.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Brookline
Guy Buckle, Md, MD
Neurology — Payments: $1.2M
Dr. Maria Houtchens, Md, MD
Neurology — Payments: $403,522
Rohit Bakshi, Md, MD
Neurology — Payments: $282,172
James Stankiewicz, M.d, M.D
Neurology — Payments: $249,278
Dr. Carolyn Bernstein, Md, MD
Neurology — Payments: $27,078
Slavenka Kam-Hansen, M.d, M.D
Neurology — Payments: $1,728